Hanmi loses Janssen obesity pact, while Yuhan signs NASH deal with Boehringer. GSK sells a Chinese site to Fosun as it opens facilities in Singapore.

Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Fosun Pharma. 

The majority of investors backed a proposal that would allow Takeda to claw back executive pay should the Shire deal not live up to expectations.

India’s Aurobindo has been savaged in an FDA warning letter for missteps that paved the pathway to the valsartan mess. 

Roche, Daiichi and AZ nab global first nods from Japan; Celgene hands back PD-1 to BeiGene; China offers incentive to generic makers.

With the list of 34 drugs, the Chinese government is encouraging drugmakers to copy them under regulator's priority review pathway.

As Bayer management predicted, it seems as though the German conglomerate’s for-sale animal health business has indeed attracted high interest.

Hansoh and Hengrui chiefs together make one of biopharma's richest families; prosecutors grill top Samsung exec; FDA cites another Aurobindo plant.